Although data for Eli Lilly’s orforglipron may have disappointed investors earlier this month, a new release of Phase III ...

Robust revenue growth and substantial profit improvement Continued exceptional executions under a clear roadmap of dual-driven growth and global innovation SAN FRANCISCO and SUZHOU ...

The bear case for Eli Lilly has now played out following the reaction to the drugmaker’s oral obesity drug trial, an analyst ...

Morgan Stanley analysts have estimated that Lilly’s GLP-1 pill could bring in as much as $40 billion in annual sales by 2033.

Shares of Chugai Pharmaceutical (OTCPK:CHGCY) closed ~6% higher on Wednesday after Eli Lilly (NYSE:LLY) announced that its ...

Eli Lilly drops a second Phase III readout for orforglipron; AbbVie committed to the psychedelic therapeutics space with the ...